

CLAIMS

1. An antibody comprising a variable (V) domain and an insert polypeptide, wherein (a) the insert polypeptide is within the framework 3 region of the VH domain between amino acid residues 73 and 74, between amino acid residues 74 and 75, or between amino acid residues 75 and 76, or (b) wherein the insert polypeptide is within the framework 3 region of the VL domain between amino acid residues 67 and 68, between amino acid residues 68 and 69, or between amino acid residues 69 and 70.
2. The antibody according to claim 1, wherein the insert polypeptide is in the VH domain: (i) between amino acid residues 73 and 74; (ii) between amino acid residues 74 and 75; or (iii) between amino acid residues 75 and 76.
3. The antibody according to claim 1, wherein one or more amino acid residues between 73 and 76 of the VH domain are replaced by the insert polypeptide.
4. The antibody according to claim 1, wherein the insert polypeptide is in the VL domain: (i) between amino acid residues 67 and 68; (ii) between amino acid residues 68 and 69; or (iii) between amino acid residues 69 and 70.
5. The antibody according to claim 1, wherein one or more amino acid residues between 67 and 70 of the VL domain are replaced by the insert polypeptide.
6. The antibody according to claim 1, which is a full-length antibody.
7. The antibody according to claim 1, which is a full-length IgG.
8. The antibody according to claim 1, which is a Fab, Fab', F(ab')₂, VHH, or scFv.
9. The antibody according to claim 1, which is humanised.
10. The antibody according to claim 1, wherein said V domain binds to human serum albumin.

11. The antibody according to claim 10, which comprises a VL domain comprising CDR-L1 having the sequence SEQ ID NO: 3; CDR-L2 having the sequence SEQ ID NO: 4; CDR-L3 having the sequence SEQ ID NO: 5.
- 5 12. The antibody according to claim 11, which comprises a VL domain comprising SEQ ID NO: 2 or SEQ ID NO: 102.
13. The antibody according to claim 12, which comprises a L chain comprising SEQ ID NO: 1.
- 10 14. The antibody according to claim 10, which comprises a VH domain comprising CDR-H1 having the sequence SEQ ID NO: 8; CDR-H2 having the sequence SEQ ID NO: 9; CDR-H3 having the sequence SEQ ID NO: 10.
- 15 15. The antibody according to claim 14, which comprises a VH domain comprising SEQ ID NO: 7 or SEQ ID NO: 103.
16. The antibody according to claim 15, which comprises a H chain comprising SEQ ID NO: 6.
- 20 17. The antibody according to claim 1, wherein the insert polypeptide is a cytokine.
18. The antibody according to claim 17, wherein the cytokine is selected from IL-10, IL-15, IL-2, G-CSF, GM-CSF and EPO.
- 25 19. The antibody according to claim 1, wherein the insert polypeptide is a second antibody.
20. The antibody according to claim 19, wherein the second antibody is an scFv or a
- 30 domain antibody.
21. The antibody according to claim 20, wherein the domain antibody is a VHH comprising a sequence selected from SEQ ID NOs: 67, 69 and 89.

22. The antibody according to claim 20, wherein the second antibody binds to the same antigen as the V domain.
23. The antibody according to claim 22, wherein the second antibody binds to a different epitope compared to the V domain.
24. The antibody according to claim 20, wherein the second antibody binds to a different antigen to the antibody comprising a V domain.
25. The antibody according to claim 20, wherein the second antibody binds to IL-17 and the antibody comprising a V domain binds to HSA.
26. The antibody according to claim 20, wherein the second antibody binds to CD3 and the antibody comprising a V domain binds to CD28.
27. The antibody according to claim 20, wherein the second antibody binds to CD28 and the antibody comprising a V domain binds to CD3.
28. An isolated DNA molecule or a pair of DNA molecules encoding the antibody according to claim 1.
29. A cloning or expression vector or a pair of cloning or expression vectors encoding the antibody according to claim 1.
30. A host cell comprising a cloning or expression vector or a pair of cloning or expression vectors according to claim 29.
31. A process for the production of an antibody as defined in claim 1, comprising culturing the host cell of claim 30 and isolating the antibody.
32. A pharmaceutical composition comprising an antibody as defined in claim 1 in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.